Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Source Data
Transparent Process
Open Access

Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction

Sergej Franz, View ORCID ProfileFabian Pott, View ORCID ProfileThomas Zillinger, View ORCID ProfileChristiane Schüler, Sandra Dapa, View ORCID ProfileCarlo Fischer, Vânia Passos, Saskia Stenzel, View ORCID ProfileFangfang Chen, Katinka Döhner, Gunther Hartmann, View ORCID ProfileBeate Sodeik, Frank Pessler, Graham Simmons, Jan Felix Drexler, View ORCID ProfileChristine Goffinet  Correspondence email
Sergej Franz
1Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany
2Vitalant Research Institute, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabian Pott
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
4Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabian Pott
Thomas Zillinger
5Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital, Venusberg-Campus 1, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Zillinger
Christiane Schüler
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
4Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christiane Schüler
Sandra Dapa
1Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlo Fischer
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlo Fischer
Vânia Passos
1Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saskia Stenzel
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
4Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fangfang Chen
6Research Group Biomarkers for Infectious Diseases, TWINCORE, Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hanover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hanover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fangfang Chen
Katinka Döhner
7Institute of Virology, Hannover Medical School, Hanover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunther Hartmann
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beate Sodeik
7Institute of Virology, Hannover Medical School, Hanover, Germany
8Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Beate Sodeik
Frank Pessler
6Research Group Biomarkers for Infectious Diseases, TWINCORE, Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hanover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hanover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham Simmons
2Vitalant Research Institute, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Felix Drexler
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Goffinet
1Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a Joint Venture Between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany
3Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany
4Berlin Institute of Health at Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christine Goffinet
  • For correspondence: christine.goffinet@charite.de
Published 2 June 2021. DOI: 10.26508/lsa.202000909
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Schematic overview of IFITM3 variants analyzed in this study.
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Endogenous human IFITM3 restricts CHIKV infection.

    (A) Immunoblot of indicated HeLa cell lysates using indicated antibodies. (B) Flow cytometry analysis of interferon-induced transmembrane expression in permeabilized HeLa cells. (C) Immunofluorescence microscopy analysis of indicated HeLa cell lines/clones upon mock treatment and treatment with 5,000 IU/ml IFN-α for 48 h (scale bar = 20 µm). (D) HeLa cells were infected with EGFP-CHIKV after a 6 h IFN-α pre-treatment duration at indicated MOIs. The percentage of EGFP-positive infected cells was quantified 24 h postinfection by flow cytometry. (E) HeLa cells were infected with MAYV-GFP at indicated MOIs The percentage of EGFP-positive infected cells was quantified 24 h postinfection by flow cytometry. (F) HeLa cells were infected with Influenza A virus at indicated MOIs. 24 h postinfection, cell-associated viral HA mRNA was quantified by quantitative RT-PCR. SNP, single nucleotide polymorphism; MFI, mean fluorescence intensity; MOI, multiplicity of infection.

    Source data are available for this figure.

    Source Data for Figure 1[LSA-2020-00909_SdataF1.zip]

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. Ectopic expression of human interferon-induced transmembrane (IFITM)-HA proteins restricts alphaviral infection by interfering with glycoprotein-mediated entry.

    HEK293T cell lines stably expressing HA-tagged IFITM proteins were generated via retroviral transduction and puromycin selection. (A) Protein expression was evaluated by immunoblotting using indicated antibodies. (B) Cells were immunostained with an anti-HA antibody and analyzed by flow cytometry, measuring IFITM surface levels in membrane-intact cells and total expression in permeabilized cells. Mean fluorescence intensity is inset for each condition. (C) Immunofluorescence microscopy of surface and intracellular immunostaining of heterologously expressed IFITM proteins using anti-HA antibody (scale bar = 20 µm). (D) IFITM-HA expressing cells were infected with EGFP-CHIKV of increasing MOIs for 24 h, and the percentage of EGFP-positive cells was quantified by flow cytometry. (E) IFITM-HA expressing cells were infected with EGFP-CHIKV or MAYV strain TRVL15537. 24 h postinfection, supernatant was collected and plaque assays were performed on Vero E6 cells to quantify infectious virus progeny. (F) Cell lines were inoculated for 48 h with lentiviral firefly luciferase-expressing reporter pseudoparticles decorated with glycoproteins of murine leukemia virus, Ebola virus, or different CHIKV lineages. Luciferase activity in transduced cells was quantified luminometrically and normalized to the vector control cell line.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. HeLa cells were infected with EGFP-CHIKV after 6 h IFN-α pre-treatment duration and with EGFP-MAYV, at indicated MOIs.

    The percentage of EGFP-positive cells was quantified 24 h postinfection by flow cytometry. Shown are dot plots from one representative experiment.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. Antiviral activity of human IFITM proteins.

    (A) Interferon-induced transmembrane-HA expressing cells were infected with EGFP-CHIKV of increasing MOIs for 24 h, and the percentage of EGFP-positive cells was quantified by flow cytometry. Shown are dot plots from one representative experiment. (B) interferon-induced transmembrane-HA expressing cells were infected with EGFP-CHIKV of increasing MOIs for 24 h, and cells were analyzed by fluorescence microscopy.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Cell-to-cell transmission of and direct infection by CHIKV differ in efficiency, but share susceptibility to interferon-induced transmembrane-mediated restriction.

    Confluent HEK293T cells were infected with EGFP-CHIKV or EGFP-HSV-1 for 6 h. Subsequently, cells were overlaid with 0.8% agarose or left untreated. (A, B) EGFP-positive cells were measured 1 and 2 d postinfection via flow cytometry and (B) microscopic analysis of CHIKV-infected cells was performed 24 h postinfection (scale bar = 500 µm). (C) Confluent HEK293T cells ectopically expressing interferon-induced transmembrane-HA proteins were infected with EGFP-CHIKV for 6 h followed by the application of a 0.8% agarose overlay where indicated. 24 h postinfection, EGFP-positive cells were measured via flow cytometry.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. Antivital activity of human IFITM proteins in the context of cell-to-cell transmission.

    (A) EGFP-positive cells were quantified 1 and 2 d postinfection with EGFP-HSV-1 and EGFP-CHIKV via flow cytometry. (B) Confluent HEK293T cells ectopically expressing interferon-induced transmembrane-HA proteins were infected with EGFP-CHIKV for 6 h followed by the application of a 0.8% agarose overlay where indicated. 24 h postinfection, EGFP-positive cells were quantified via flow cytometry. Shown are dot plots from one representative experiment.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. Reduction of cell surface expression of antiviral interferon-induced transmembrane (IFITM) proteins in CHIKV-infected cells.

    (A) Indicated HEK293T cells were infected with EGFP-CHIKV (MOI 10) for 24 h and were immunostained with an anti-HA antibody for flow cytometry. (B) Quantification of IFITM-HA expression in EGFP-positive relative to EGFP-negative cells after infection with EGFP-CHIKV for 24 h. (C) Immunoblot analysis of IFITM-HA expression in cells infected with EGFP-CHIKV at the indicated MOIs and quantitative analysis thereof. (D) Indicated HEK293T cell lines were infected with EGFP-CHIKV (MOI 10) for 24 h. Permeabilized cells were immunostained with an anti-HA antibody and analyzed microscopically (scale bar = 20 µm). Arrowheads indicate EGFP-positive cells with IFITM-HA expression (red) or lack thereof. (E) Indicated cell lines were transfected individually with full-length EGFP-CHIKV RNA and HIV-1 EGFP DNA and were immunostained with an anti-HA antibody. Mean fluorescence intensitys of IFITM-HA EGFP-positive cells were determined via flow cytometry and normalized to the mean fluorescence intensity of EGFP-negative cells. (F) Quantification of IFITM3-HA surface level 24 h after individual transfection of HEK293T IFITM-3-HA cells with full length EGFP-CHIKV mRNA or RNA encoding the non-structural proteins 1–4 and EGFP.

    Source data are available for this figure.

    Source Data for Figure 4[LSA-2020-00909_SdataF1.zip]

  • Figure S5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S5. Indicated cell lines were transfected individually with full-length EGFP-CHIKV RNA and HIV-1 EGFP DNA and were immunostained with an anti-HA antibody.

    Shown are dot plots from one representative experiment.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Posttranscriptional reduction of endogenous IFITM3 expression in CHIKV-infected cells.

    (A) HeLa cells were infected with EGFP-CHIKV (MOI 100) for 24 h, permeabilized, and immunostained for IFITM3 before microscopic analysis. Dotted lines indicate the border of EGFP-positive cells (scale bar = 50 µm). (B) Quantification of microscopic images of infected HeLa cells. IFITM3 mean fluorescence intensity (MFI) was determined using ImageJ and is plotted against EGFP MFI (mock cells n = 50; CHIKV-infected cells n = 80). (C) HeLa cells were infected with EGFP-CHIKV and EGFP-MAYV (MOI 10) for 24 h. Subsequently, permeabilized cells were stained for IFITM3, ISG15, MX1, or BST-2 and MFI values were normalized to EGFP-negative cells. (D) HeLa cells were infected with EGFP-CHIKV or EGFP-MAYV (MOI 10) and 24 h postinfection, IFITM3, and IFIT1 mRNA levels were measured by quantitative RT-PCR.

    Source data are available for this figure.

    Source Data for Figure 5[LSA-2020-00909_SdataF1.zip]

  • Figure S6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S6. HeLa cells were infected with EGFP-CHIKV (MOI 10) for 24 h.

    Subsequently, permeabilized cells were stained for IFITM3, ISG15, MX1, or BST-2. Shown are dot plots from one representative experiment.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Reduction of virion infectivity through expression of IFITM3 in virus-producing cells.

    (A) Immunoblot analysis of lysates and concentrated supernatants of 293T and Hela cells transfected with full-length EGFP-CHIKV mRNA or pBR-NL4.3-GFP plasmid at 24 h posttransfection. (B) Viral titers produced by cells transfected in (A) normalized to the relative amount of GFP-positive cells. Viral titers were determined by titration and flow cytometric analysis of supernatants on 293T cells (CHIKV) or Tzm-bl cells (HIV), respectively. (C) Relative specific infectivity of produced virions as calculated by the infectivity per abundance of viral capsid.

    Source data are available for this figure.

    Source Data for Figure 6[LSA-2020-00909_SdataF1.zip]

Tables

  • Figures
    • View popup
    Table 1.

    List of IFITM3 variants generated by gene editing of HeLa cells

    IFITM3 cloneType of gene editGene edit (nt position refers to NM_021034.3)Genomic DNA sequenceGuide RNA target (PAM)
    KO+1 frameshiftInsertion of A between nts 84 and 85CCTGTCA[+A]ACAGTGGCCAGGGGGGCTGGCCACTGTTGAC(AGG)
    Δexon1DeletionDeletion of 381 nts post nt 36CGACCGCCGCTGGTCTT [deletion of 381 nt]1:CGACCGCCGCTGGTCTTCGC(TGG)
    TCCCGTGTGTGCCCACG
    2:CGTGGGCACACACGGGACAG(AGG)
    SNP rs12252-CT to C transitionT89CCCTGTCAACAGCGGCCAGCCCCCguide:GGGGGCTGGCCACTGTTGAC(AGG)
    +HDR-Donor: CTGGACACCATGAATCACACTGTCCAAACCTTCTTCTCTCCTGT
    CAACAGCGGCCAGCCCCCCAACTATGAGATGCTCAAGGAGGAGCAC
    Δ1st ATGDeletionDeletion of 31 nts post nt 36CGACCGCCGCTGGTCTT [deletion of 31 nt]1:CGACCGCCGCTGGTCTTCGC(TGG)
    2:TGACAGGAGAGAAGAAGGTT(TGG)
    CTTCTTCTCTCCTGTCAA
    • nt, nucleotide.

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human IFITM3 restricts alphaviruses
Sergej Franz, Fabian Pott, Thomas Zillinger, Christiane Schüler, Sandra Dapa, Carlo Fischer, Vânia Passos, Saskia Stenzel, Fangfang Chen, Katinka Döhner, Gunther Hartmann, Beate Sodeik, Frank Pessler, Graham Simmons, Jan Felix Drexler, Christine Goffinet
Life Science Alliance Jun 2021, 4 (7) e202000909; DOI: 10.26508/lsa.202000909

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human IFITM3 restricts alphaviruses
Sergej Franz, Fabian Pott, Thomas Zillinger, Christiane Schüler, Sandra Dapa, Carlo Fischer, Vânia Passos, Saskia Stenzel, Fangfang Chen, Katinka Döhner, Gunther Hartmann, Beate Sodeik, Frank Pessler, Graham Simmons, Jan Felix Drexler, Christine Goffinet
Life Science Alliance Jun 2021, 4 (7) e202000909; DOI: 10.26508/lsa.202000909
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 4, No. 7
July 2021
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Immunology
  • Microbiology, Virology & Host Pathogen Interaction

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • ERK activation blocks ciliary assembly
  • KRAS-mediated (sub)complexes
  • Preference of CAMSAP3 and expansion of microtubule lattice
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.